Get access

An innovative approach to integrated medicines management

Authors

  • Claire Scullin PhD,

    1. Research Fellow, Clinical and Practice Research Group, School of Pharmacy, Queen’s University Belfast, Belfast, UK
    Search for more papers by this author
  • Michael G. Scott PhD,

    1. Chief Pharmacist,
    Search for more papers by this author
  • Anita Hogg BSc,

    1. Senior Pharmacist, Antrim Area Hospital Academic Practice Unit, United Hospitals Trust, Antrim, UK
    Search for more papers by this author
  • James C. McElnay PhD

    Corresponding author
    1. Dean of Faculty of Medicine, Health and Life Sciences and Professor of Pharmacy Practice, School of Pharmacy, Queen’s University Belfast, Belfast, UK
      Professor James C. McElnay
      Faculty of Medicine, Health and Life Sciences
      Queen’s University Belfast
      71 University Road
      Belfast BT7 1NF
      UK
      E-mail: j.mcelnay@qub.ac.uk
    Search for more papers by this author

Professor James C. McElnay
Faculty of Medicine, Health and Life Sciences
Queen’s University Belfast
71 University Road
Belfast BT7 1NF
UK
E-mail: j.mcelnay@qub.ac.uk

Abstract

Rationale, aims and objectives  To determine whether an increased input by clinical pharmacists at each stage of the patient’s hospital journey, from admission through discharge, resulted in an enhanced level of patient care as measured by a number of clinical and economic outcomes.

Methods  This project was designed to address medicines management issues in patients deemed at risk of drug-related problems. During the project, these latter patients at the time of admission were randomly assigned to an integrated medicines management (IMM) service group (n = 371) or regular hospital care group (n = 391). The IMM service involved comprehensive pharmaceutical care provided by a pharmacy team throughout each of three stages: patient admission, inpatient monitoring and counselling, and patient discharge.

Results  Patients who received the IMM service benefited from a reduced length of hospital stay [by 2 days (P = 0.003; independent samples t-test loge)]. IMM patients also had a decreased rate of readmission over a 12-month follow-up period (40.8% vs. 49.3%; p = 0.027; Fisher’s exact test) and an increased time to readmission [20 days longer (P = 0.0356; log rank test)]. A numbers-needed-to-treat calculation indicated that for approximately every 12 patients receiving the IMM service, one readmission to hospital, within 12 months of discharge, would be prevented. The new service was welcomed by cognate health care professionals.

Conclusion  The IMM service proved very effective and can be used as a template to support the implementation of comprehensive pharmaceutical care as a routine service across Northern Ireland and beyond.

Get access to the full text of this article

Ancillary